Case Number

Sample Size

Outcome

Reference

1

4

This study showed that hUC-MSC transplantation is a safe and an effective treatment for ITP, with an annual optimal period of transplantation.

[32]

2

2

Both paediatric patients, one diagnosed with AML with MDS-related changes and monosomy 7 and the other with MDS with monosomy 7, were treated successfully following UCB-HSCT transplantation.

[34]

3

1

Following the transplantation of hUC-MSCs, the IPF patient showed improvements in term of quality of life, physical performance and respiratory parameters (lung function, 6MWD and CT fibrosis score).

[35]

4

34

The patients-suffering from moderate to severe AD-responded positively to hUCB-MSCs transplantation, showing a dose-dependent therapeutic effect.

[36]

5

14

The test group showed a significantly higher mean root coverage compared to the control group.

[40]

6

1

8 months post-treatments, the patient had a complete resolution of all symptoms, showed no complications related to the HU-MSCs treatment and all medications were discontinued.

[41]